CYP2D6 and CYP2C19 genotypes in an elderly Swedish population

European Journal of Clinical Pharmacology

Volumn 54, Issue 6, 1998, Pages 479-481

  Yamada, H ^a,b   Dahl, M L ^a   Lannfelt, L ^a   Viitanen, M ^a   Winblad, B ^a   Sjoqvist F ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

Author keywords

CYP2C19; CYP2D6; Elderly

Indexed keywords

CYTOCHROME P450 CYP 2 C 19; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; MEPHENYTOIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEMENTIA; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMERASE CHAIN REACTION; REFERENCE VALUES; SWEDEN;

EID: 0031682185     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050497     Document Type: Article

References (13)

1. Agúndez JAG, Jiménez-Jiménez FJ, Luengo A, Bernal ML, Molina JA, Ayuso L, Vasquez A, Parra J, Duarte J, Coria F, Ladero JM, Alvarez JC, Benítez J (1995) Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 57: 291-298
2. Agúndez JAG, Rodríguez I, Olivera M, Ladero JM, García MA, Ribera JM, Benítez J (1997) CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Age Ageing 26: 147-151
3. Alván G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533-537
4. Beers MH, Ouslander JG (1989) Risk factors in geriatric drug prescribing; a practical guide to avoiding problems. Drugs 37: 105-112
5. Bertilsson L, Dahl M-L (1996) Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 5: 200-223
6. Caporaso N, Landi MT, Vineis P (1991) Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics 1: 4-19
7. Chang M, Dahl M-L, Tybring G, Götharsson E, Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5: 358-363
8. Dahl M-L, Johansson I, Porsmyr Palmertz M, Ingelman-Sundberg M, Sjöqvist F (1992) Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 51: 12-17
9. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994a) The major genetic defect responsible for the polymorphism of 5-mephenytoin metabolism in humans. J Biol Chem 269: 15419-15422
10. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994b) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46: 594-598
11. Fratiglioni L, Viitanen M, Bäckman L, Sandman P-O, Winblad B (1992) Occurrence of dementia in advanced age: the study design of the Kungsholmen project. Neuroepidemiology 11[suppl 1]: 29-36
12. Gonzalez FJ (1992) Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 13: 346-352
13. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529-532